Back to search
FDAFDA · Food and drugs·Recall number D-0067-2021

Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, 100 count bottles, Rx Only. Manufactured by: Nostrum Laboratories, Inc. Kansas City, MO 64120. NDC 29033-056-01

Published November 11, 2020 · Recall initiated: October 23, 2020

Summary

FDA records drug Class II recall D-0067-2021, published November 11, 2020 and initiated October 23, 2020. Recalling firm: Nostrum Laboratories Inc; Status: Ongoing; Reported quantity: 12,967 bottles; Lot: MET200101, MET200301 EXP 05/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Nostrum Laboratories Inc
Distributor
Nationwide
Lot
MET200101, MET200301 EXP 05/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, 100 count bottles, Rx Only. Manufactured by: Nostrum Laboratories, Inc. Kansas City, MO 64120. NDC 29033-056-01 recalled?

Yes. FDA published recall D-0067-2021 on November 11, 2020. Reported hazard: CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

What should I do if I have this product?

Voluntary: Firm initiated · Letter